Thonzonium (bromide)

Thonzonium (bromide)

• CAS Number: 553-08-2
• UNSPSC Description: Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM)[1][2][3].
• Target Antigen: Bacterial; Proton Pump
• Type: Reference compound
• Related Pathways: Anti-infection;Membrane Transporter/Ion Channel
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/Thonzonium-bromide.html
• Purity: 99.86
• Solubility: DMSO : ≥ 30 mg/mL|H2O : 100 mg/mL (ultrasonic)
• Smiles: CCCCCCCCCCCCCCCC[N+](C)(CCN(CC1=CC=C(OC)C=C1)C2=NC=CC=N2)C.[Br-]
• Molecular Weight: 591.71
• References & Citations: [1]Zhu X, et al. Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016;104:118-130.|[2]Chan CY, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). J Biol Chem. 2012;287(13):10236-10250.|[3]Sims KR, et al. Enhanced design and formulation of nanoparticles for anti-biofilm drug delivery. Nanoscale. 2018;11(1):219-236.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, stored under nitrogen)
• Clinical Information: Launched